CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 79% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Rain Therapeutics Inc. - RAIN CFD

1.05
0.94%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026207 %
Charges from full value of position ($-4.98)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026207%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003985 %
Charges from full value of position ($0.76)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003985%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Rain Oncology Inc ESG Risk Ratings

High Medium Low Negligible

‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 1.06
Open* 1.04
1-Year Change* -86.73%
Day's Range* 1.04 - 1.05
52 wk Range 0.82-14.48
Average Volume (10 days) 145.67K
Average Volume (3 months) 3.75M
Market Cap 38.92M
P/E Ratio -100.00K
Shares Outstanding 36.38M
Revenue N/A
EPS -2.07
Dividend (Yield %) N/A
Beta -100.00K
Next Earnings Date Mar 7, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Nov 27, 2023 1.06 -0.02 -1.85% 1.08 1.08 1.06
Nov 24, 2023 1.07 0.05 4.90% 1.02 1.07 1.02
Nov 22, 2023 1.04 -0.01 -0.95% 1.05 1.05 1.03
Nov 21, 2023 1.05 -0.01 -0.94% 1.06 1.06 1.03
Nov 20, 2023 1.06 0.00 0.00% 1.06 1.07 1.03
Nov 17, 2023 1.07 0.03 2.88% 1.04 1.07 1.00
Nov 16, 2023 1.02 -0.07 -6.42% 1.09 1.09 1.02
Nov 15, 2023 1.09 0.00 0.00% 1.09 1.10 1.08
Nov 14, 2023 1.07 -0.04 -3.60% 1.11 1.12 1.06
Nov 13, 2023 1.08 0.05 4.85% 1.03 1.11 1.02
Nov 10, 2023 1.05 0.07 7.14% 0.98 1.08 0.98
Nov 9, 2023 1.00 -0.05 -4.76% 1.05 1.09 0.97
Nov 8, 2023 1.08 0.04 3.85% 1.04 1.10 1.04
Nov 7, 2023 1.09 0.01 0.93% 1.08 1.09 1.07
Nov 6, 2023 1.09 0.03 2.83% 1.06 1.10 1.06
Nov 3, 2023 1.10 0.02 1.85% 1.08 1.10 1.06
Nov 2, 2023 1.08 0.04 3.85% 1.04 1.10 1.04
Nov 1, 2023 1.06 0.03 2.91% 1.03 1.07 1.02
Oct 31, 2023 1.05 0.03 2.94% 1.02 1.05 1.02
Oct 30, 2023 1.04 -0.02 -1.89% 1.06 1.06 1.03

Rain Therapeutics Inc. Events

Time (UTC) Country Event
Thursday, March 7, 2024

Time (UTC)

21:00

Country

US

Event

Q4 2023 Rain Oncology Inc Earnings Release
Q4 2023 Rain Oncology Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019
Total revenue 0 0 0 0
Total Operating Expense 77.136 51.512 18.958 10.828
Selling/General/Admin. Expenses, Total 15.736 10.739 3.591 3.538
Research & Development 61.4 40.773 10.2 7.29
Unusual Expense (Income) 5.167 0
Operating Income -77.136 -51.512 -18.958 -10.828
Interest Income (Expense), Net Non-Operating 1.415 0.119 -0.103 0.177
Other, Net -0.001 -2.022 -0.251
Net Income Before Taxes -75.721 -51.394 -21.083 -10.902
Net Income After Taxes -75.724 -51.392 -21.083 -10.902
Net Income Before Extra. Items -75.724 -51.392 -21.083 -10.902
Net Income -75.724 -51.392 -21.083 -10.902
Income Available to Common Excl. Extra. Items -75.724 -51.394 -21.083 -10.902
Income Available to Common Incl. Extra. Items -75.724 -51.394 -21.083 -10.902
Diluted Net Income -75.724 -51.394 -21.083 -10.902
Diluted Weighted Average Shares 27.9855 19.4058 25.9692 25.9692
Diluted EPS Excluding Extraordinary Items -2.70584 -2.64838 -0.81185 -0.41981
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -2.70584 -2.64838 -0.61288 -0.41981
Total Adjustments to Net Income -0.002
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 23.231 21.743 23.557 18.411 17.718
Selling/General/Admin. Expenses, Total 5.414 5.066 4.479 3.901 3.461
Research & Development 14.98 16.677 19.078 14.51 14.257
Operating Income -23.231 -21.743 -23.557 -18.411 -17.718
Interest Income (Expense), Net Non-Operating 1.167 1.259 0.882 0.37 0.107
Net Income Before Taxes -22.064 -20.484 -22.675 -18.041 -17.611
Net Income After Taxes -22.064 -20.484 -22.678 -18.041 -17.611
Net Income Before Extra. Items -22.064 -20.484 -22.678 -18.041 -17.611
Net Income -22.064 -20.484 -22.678 -18.041 -17.611
Income Available to Common Excl. Extra. Items -22.064 -20.484 -22.678 -18.041 -17.611
Income Available to Common Incl. Extra. Items -22.064 -20.484 -22.678 -18.041 -17.611
Diluted Net Income -22.064 -20.484 -22.678 -18.041 -17.611
Diluted Weighted Average Shares 36.3633 36.3399 32.3354 26.5646 26.5295
Diluted EPS Excluding Extraordinary Items -0.60677 -0.56368 -0.70134 -0.67914 -0.66383
Dividends per Share - Common Stock Primary Issue 0 0 0 0 0
Diluted Normalized EPS -0.52875 -0.56368 -0.70134 -0.67914 -0.66383
Other, Net 0
Unusual Expense (Income) 2.837
  • Annual
  • Quarterly
2022 2021 2020 2019
Total Current Assets 133.628 146.146 59.525 6.274
Cash and Short Term Investments 130.454 140.218 58.863 5.794
Cash & Equivalents 61.955 24.78 58.863 5.794
Prepaid Expenses 2.432 5.252 0.53 0.37
Other Current Assets, Total 0.742 0.676 0.132 0.11
Total Assets 135.18 147.14 61.08 7.395
Property/Plant/Equipment, Total - Net 0.351 0.551 0.546 0.692
Property/Plant/Equipment, Total - Gross 0.587 0.707 0.631 0.725
Accumulated Depreciation, Total -0.236 -0.156 -0.085 -0.033
Note Receivable - Long Term 0.052 0.298 0.549 0.354
Other Long Term Assets, Total 1.149 0.145 0.46 0.075
Total Current Liabilities 21.966 16.315 3.419 1.224
Accounts Payable 7.146 6.112 0.816 0.261
Accrued Expenses 14.82 10.203 1.076 0.684
Notes Payable/Short Term Debt 0 0 0 0
Other Current Liabilities, Total 1.527 0.279
Total Liabilities 22.144 16.636 3.8 4.496
Total Long Term Debt 0 0 0 2.751
Long Term Debt 0 2.751
Other Liabilities, Total 0.178 0.321 0.381 0.521
Total Equity 113.036 130.504 57.28 2.899
Redeemable Preferred Stock 0 0 95.024 20.147
Common Stock 0.037 0.027 0.004 0.003
Additional Paid-In Capital 278.853 220.53 1.149 0.236
Retained Earnings (Accumulated Deficit) -165.688 -89.964 -38.57 -17.487
Total Liabilities & Shareholders’ Equity 135.18 147.14 61.08 7.395
Total Common Shares Outstanding 36.2903 26.4758 25.9692 25.9692
Preferred Stock - Non Redeemable, Net -0.327
Short Term Investments 68.499 115.438
Other Equity, Total -0.166 -0.089
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 80.816 90.993 112.975 133.628 93.745
Cash and Short Term Investments 77.32 86.29 109.77 130.454 90.708
Cash & Equivalents 37.312 40.076 44.1 61.955 39.834
Prepaid Expenses 2.665 3.969 2.502 2.432 2.615
Total Assets 82.06 91.723 114.178 135.18 94.635
Property/Plant/Equipment, Total - Net 1.064 0.55 0.299 0.351 0.394
Other Long Term Assets, Total 0.18 0.18 0.851 1.149 0.443
Total Current Liabilities 14.477 18.331 19.48 21.966 13.013
Accounts Payable 8.973 5.801 7.421 7.146 4.084
Accrued Expenses 5.504 12.53 12.059 14.82 8.929
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 14.541 18.434 19.621 22.144 13.226
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.064 0.103 0.141 0.178 0.213
Total Equity 67.519 73.289 94.557 113.036 81.409
Redeemable Preferred Stock 0 0 0 0
Preferred Stock - Non Redeemable, Net
Common Stock 0.037 0.037 0.037 0.037 0.027
Additional Paid-In Capital 282.816 281.588 280.739 278.853 224.694
Retained Earnings (Accumulated Deficit) -215.27 -208.236 -186.172 -165.688 -143.01
Total Liabilities & Shareholders’ Equity 82.06 91.723 114.178 135.18 94.635
Total Common Shares Outstanding 36.3757 36.3757 36.3632 36.2903 26.5648
Short Term Investments 40.008 46.214 65.67 68.499 50.874
Other Equity, Total -0.064 -0.1 -0.047 -0.166 -0.302
Note Receivable - Long Term 0 0.053 0.052 0.053
Other Current Assets, Total 0.831 0.734 0.703 0.742 0.422
Property/Plant/Equipment, Total - Gross 1.489 0.821 0.553 0.587 0.612
Accumulated Depreciation, Total -0.425 -0.271 -0.254 -0.236 -0.218
  • Annual
  • Quarterly
2022 2021 2020 2019
Net income/Starting Line -75.724 -51.394 -21.083 -10.902
Cash From Operating Activities -63.199 -37.463 -11.231 -11.182
Cash From Operating Activities 0.08 0.071 0.052 0.028
Non-Cash Items 3.515 8.672 8.191 0.519
Changes in Working Capital 8.93 5.188 1.609 -0.827
Cash From Investing Activities 47.194 -118.235 -5.191 -0.144
Capital Expenditures -0.008 -0.128 -0.024 -0.144
Other Investing Cash Flow Items, Total 47.202 -118.107 -5.167 0
Cash From Financing Activities 53.18 121.615 69.491 2.5
Financing Cash Flow Items -3.467 -11.872 -0.166 0
Issuance (Retirement) of Stock, Net 56.647 133.487 63.222 0
Issuance (Retirement) of Debt, Net 0 6.435 2.5
Net Change in Cash 37.175 -34.083 53.069 -8.826
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -20.484 -75.724 -53.046 -35.005 -17.394
Cash From Operating Activities -21.839 -63.199 -49.905 -34.542 -17.11
Cash From Operating Activities 0.018 0.08 0.062 0.044 0.022
Non-Cash Items 0.998 3.515 2.556 2.709 1.275
Changes in Working Capital -2.371 8.93 0.523 -2.29 -1.013
Cash From Investing Activities 3.518 47.194 64.386 52.76 13.436
Capital Expenditures -0.008 0 0 0
Cash From Financing Activities 0.466 53.18 0.573 0.411 0.399
Financing Cash Flow Items -0.089 -3.467 0
Net Change in Cash -17.855 37.175 15.054 18.629 -3.275
Other Investing Cash Flow Items, Total 3.518 47.202 64.386 52.76 13.436
Issuance (Retirement) of Stock, Net 0.555 56.647 0.573 0.411 0.399
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
Tang Capital Management, LLC Hedge Fund 14.5921 4024486 284145 2023-10-13 MED
BVF Partners L.P. Hedge Fund 12.7873 3526729 0 2023-08-10 LOW
Vellanki (Avanish) Individual Investor 9.2491 2550910 -59618 2023-03-01
Samsara BioCapital, LLC Venture Capital 7.3769 2034552 -226100 2023-06-30 LOW
Boxer Capital, L.L.C. Hedge Fund 4.1777 1152212 0 2023-06-30 LOW
Berger (Franklin Milan) Individual Investor 3.6447 1005207 0 2023-03-01 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 3.3666 928499 855288 2023-06-30 LOW
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 3.282 905171 24081 2023-06-30 LOW
Polen Capital Management, LLC Investment Advisor/Hedge Fund 2.6088 719513 0 2023-08-31 LOW
Acadian Asset Management LLC Investment Advisor/Hedge Fund 2.3907 659349 656571 2023-06-30 MED
Millennium Management LLC Hedge Fund 2.1796 601143 556303 2023-06-30 HIGH
Doebele (Robert) Individual Investor 1.7289 476827 0 2023-03-01 LOW
Acuitas Investments LLC Investment Advisor/Hedge Fund 1.4839 409256 409256 2023-09-30 HIGH
Two Sigma Investments, LP Hedge Fund 1.3657 376670 298668 2023-06-30 HIGH
Western Standard, LLC Hedge Fund 1.2585 347089 347089 2023-06-30 HIGH
Ghost Tree Capital, LLC Hedge Fund 1.1784 325000 75000 2023-06-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 1.1728 323471 161578 2023-06-30 LOW
Goldman Sachs & Company, Inc. Research Firm 0.8652 238616 153534 2023-06-30 MED
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.8143 224571 169508 2023-06-30 LOW
Exchange Traded Concepts, LLC Investment Advisor 0.4616 127306 14494 2023-09-30 HIGH

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Rain Therapeutics Inc. Company profile

About Rain Therapeutics Inc

Rain Therapeutics Inc. (Rain) is a clinical-stage precision oncology company. The Company is engaged in developing therapies that target oncogenic drivers. The Company's lead product candidate, RAIN-32 (milademetan) is a small molecule, oral inhibitor of mouse double minute 2 (MDM2). It is being developed in patients with MDM2 amplified or overexpressed cancers. MDM2 inhibition is a treatment approach due to dose-limiting on-target hematologic toxicities. The initial development opportunity for RAIN-32 be in patients with MDM2-amplified tumors, beginning with well-differentiated/de-differentiated (WD/DD) liposarcoma (LPS) patients. Rain is also developing a preclinical program that is focused on inducing synthetic lethality in cancer cells by inhibiting RAD52. RAD inhibition leads to synthetic lethality in the DNA damage repair (DDR) pathway.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Rain Therapeutics Inc revenues was not reported. Net loss applicable to common stockholders increased from $21.1M to $51.4M. Higher net loss reflects Research and development expense increase from $9.6M to $38.3M (expense), General and administrative expense increase from $3.3M to $10.1M (expense), Stock-based Compensation in R&D increase from $581K to $2.5M (expense).

Industry: Biotechnology & Medical Research (NEC)

8000 Jarvis Avenue
Suite 204
NEWARK
CALIFORNIA 94560
US

Income Statement

  • Annual
  • Quarterly

News

A weaker Dollar drives gold higher

Gold prices have returned above $US2000 per ounce. We run through the factors driving gold and the commodity’s key technicals.

13:49, 28 November 2023

Q3 US Earnings Recap: Profits surprise to the upside, but outlook remains uncertain

US earnings for the third quarter were far better than expected. However, uncertainty about the outlook for company profits continues. We review the quarterly earnings and look ahead to what the markets expect from S&P 500 companies going forward.

13:20, 28 November 2023

RBNZ Preview: Rates expected to remain unchanged at final meeting of 2023

The RBNZ meets for the final time this year on Wednesday, 29th of November, 2023. We preview what to expect and how it could impact the New Zealand Dollar.

13:04, 28 November 2023

Crude prices slide on OPEC+ uncertainty

Crude prices have chopped sideways amid signs of turmoil within OPEC+. We look at the fundamentals of the oil market and the technical levels of WTI.

12:55, 28 November 2023
GBP

UK AUTUMN BUDGET: Will Hunt cut taxes? How will GBP react this time around?

UK Chancellor Hunt will deliver the 2023 autumn statement to MPs on Wednesday 22 November.

10:48, 21 November 2023

Gold Rises as Traders price-in Fed Rate Cuts

Gold prices have declined despite a drop in Treasury yields and a weaker US Dollar. We look at the key drivers and technical levels for the gold price.

13:17, 20 November 2023
Gold bars

XAU/USD Latest: Gold advances as weaker data weighs on US yields

Gold moves higher as softer economic data weighs on US yields and the dollar

13:43, 17 November 2023

People also watch

US100

16,015.50 Price
+0.340% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 22:00 (UTC)
Spread 1.8

Oil - Crude

76.73 Price
+2.120% 1D Chg, %
Long position overnight fee -0.0187%
Short position overnight fee -0.0032%
Overnight fee time 22:00 (UTC)
Spread 0.030

BTC/USD

37,934.90 Price
+2.250% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 22:00 (UTC)
Spread 106.00

Gold

2,045.30 Price
+1.530% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0110%
Overnight fee time 22:00 (UTC)
Spread 0.30

Still looking for a broker you can trust?

Join the 570.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading